PHILADELPHIA — In an era where medical advocacy is increasingly driven by those living with the conditions they represent, few voices resonate as powerfully as that of Dr. Kelly Shanahan. As the President of METAvivor, a non-profit organization dedicated to funding research for Stage IV metastatic breast cancer (MBC), Dr. Shanahan recently completed a high-profile advocacy circuit that took her from the corporate boardrooms of San Francisco to the emotional heart of the MBC community in Philadelphia.
Her journey, documented in a recent address to the METAvivor community, highlights a pivotal moment for the organization. Through strategic partnerships with pharmaceutical giants and grassroots connections at the 20th Living Beyond Breast Cancer (LBBC) MBC conference, METAvivor is reinforcing its role as a primary catalyst for change in the oncology landscape.
Main Facts: A Convergence of Advocacy and Recognition
The past month marked a significant milestone for METAvivor’s leadership. Dr. Kelly Shanahan and fellow board member Janice Cowden were formally recognized as "Changemakers" by Living Beyond Breast Cancer, an honor that underscores their relentless pursuit of better outcomes for the MBC community. This recognition comes at a time when the organization is expanding its footprint in both the scientific and patient-support sectors.
The advocacy tour began in San Francisco, where Dr. Shanahan represented METAvivor at two high-level Genentech events: the “Insight Exchange,” focused specifically on oncology, and the “Experience Exchange,” which brought together representatives from over 125 organizations spanning a vast spectrum of diseases. These exchanges are designed to bridge the gap between pharmaceutical development and the lived experiences of patients, ensuring that the "patient voice" is not just heard but integrated into the research and development pipeline.
Following the West Coast meetings, the focus shifted to Philadelphia for the 20th annual LBBC MBC conference. This event served as a critical touchstone for the metastatic community, offering a space for emotional connection, peer support, and the dissemination of cutting-edge scientific information. For METAvivor, the conference was also a rare opportunity for its geographically dispersed board of directors to convene in person, moving beyond the "tiny squares on Zoom" to strategize for the organization’s future.
Chronology of Advocacy: From Policy to Personal Connection
The sequence of events over the last several weeks illustrates the multifaceted nature of modern medical advocacy.
The San Francisco Exchanges (Early Month):
In San Francisco, Dr. Shanahan engaged in high-level dialogues at Genentech. The "Insight Exchange" provided a platform to discuss the specific needs of MBC patients in the context of oncology research. This was followed by the "Experience Exchange," a broader gathering of 125 patient advocacy groups. These meetings are essential for "A to Z" disease representation, allowing leaders like Dr. Shanahan to share best practices and ensure that the unique challenges of metastatic cancer—such as the need for continuous, life-long treatment—are prioritized by drug developers.
The Philadelphia LBBC Conference (Mid-Month):
The transition to Philadelphia marked a shift from the corporate to the communal. The LBBC MBC conference celebrated its 20th year, standing as one of the most significant gatherings for those living with Stage IV breast cancer. For Dr. Shanahan, this was a dual-purpose mission: acting as a representative of METAvivor and participating as a patient and panelist.
During the conference, Dr. Shanahan and Janice Cowden received their "Changemaker" awards. Dr. Shanahan also participated in a panel titled “The emotional impact of living long-term with MBC.” As a physician who identifies as "sciency" and "evidence-based," Dr. Shanahan noted that discussing the emotional toll was outside her typical comfort zone. However, she utilized the platform to discuss how advocacy served as a vital coping mechanism after the loss of her career as an OB/GYN due to her diagnosis.
Board Consolidation and Grassroots Outreach:
The conference served as an unofficial headquarters for METAvivor. Eight board members from across the United States—spanning from California to New Jersey, and Massachusetts to Florida—attended in person. This physical gathering allowed the leadership team, including Executive Director Crystal Moore, to strengthen their working relationships. Meanwhile, the METAvivor booth, manned by volunteer Tim Bigelow, became a hub for recruitment, attracting individuals interested in grant review and peer-to-peer leadership training.
Supporting Data: The MBC Landscape and METAvivor’s Mission
To understand the significance of Dr. Shanahan’s advocacy, one must look at the sobering statistics and the historical funding gap associated with metastatic breast cancer.
The Reality of MBC:
Metastatic breast cancer, also known as Stage IV, occurs when cancer spreads beyond the breast to vital organs such as the bones, liver, lungs, or brain. While early-stage breast cancer has seen a dramatic increase in survival rates, MBC remains a terminal diagnosis. According to the Metastatic Breast Cancer Network, approximately 627,000 women die from breast cancer globally each year, with nearly all of those deaths resulting from metastatic disease.
The Funding Disparity:
One of the primary drivers of METAvivor’s mission is the historical lack of research funding specifically for metastasis. While billions of dollars are raised annually for breast cancer awareness and early detection, estimates suggest that only 2% to 5% of overall breast cancer research funding is dedicated to Stage IV disease. METAvivor was founded to address this disparity, pledging that 100% of its net donations go directly to MBC research grants.
Peer-to-Peer Growth:
The call for "peer-to-peer leaders" at the Philadelphia conference reflects a growing trend in patient care. Research indicates that patients with terminal illnesses who participate in support groups led by individuals with the same diagnosis experience lower levels of distress and a higher quality of life. METAvivor’s initiative to train leaders to start local support groups is a direct response to the isolation often felt by MBC patients in traditional "pink ribbon" support groups, which often focus on "survivorship" and "beating" the disease—narratives that do not always align with the reality of Stage IV.
Official Responses: Leadership and Community Impact
The recognition of Dr. Shanahan and Janice Cowden as "Changemakers" by Living Beyond Breast Cancer (LBBC) serves as an official endorsement of METAvivor’s impact. LBBC, a prominent national non-profit, selects individuals who have made "significant contributions to the breast cancer community through their leadership, advocacy, and dedication."
In her response to the honor, Dr. Shanahan emphasized the symbiotic relationship between advocacy and personal resilience. "Getting involved with MBC advocacy in general and METAvivor in particular, has really helped me cope with this diagnosis and the loss of my career," she stated. This sentiment is echoed by many in the community who find that shifting from "patient" to "advocate" provides a sense of agency in a situation that often feels powerless.
The presence of Executive Director Crystal Moore and a large portion of the board in Philadelphia also signals a strategic alignment. "We usually see each other as tiny squares on Zoom," Shanahan remarked, highlighting the importance of human connection in organizational leadership. This unity is crucial as METAvivor continues to vet and fund high-impact research grants that seek to turn MBC from a terminal illness into a manageable chronic condition.
Implications: The Future of MBC Advocacy and Personal Hope
The implications of this month’s activities extend far beyond a single conference. They represent a broader shift in how terminal diseases are managed and perceived.
The Evolution of Clinical Trials:
Perhaps the most poignant implication of the current advocacy landscape is found in Dr. Shanahan’s personal health update. After transitioning to a new clinical trial, her recent scans showed that every one of her metastases had become less active after only two months. This success is not just a personal victory; it is a testament to the efficacy of the very research METAvivor funds. It highlights the critical importance of patient participation in clinical trials and the potential for new, targeted therapies to extend life.
Bridging the Science-Emotion Gap:
Dr. Shanahan’s participation in the emotional impact panel signals a maturing of the advocacy movement. There is a growing recognition that "evidence-based" medicine must be paired with comprehensive emotional support. By discussing the loss of her career and the psychological weight of long-term survival with a terminal diagnosis, Dr. Shanahan is helping to de-stigmatize the mental health challenges associated with Stage IV cancer.
A Call to Action:
The surge of interest at the METAvivor booth in Philadelphia suggests a burgeoning grassroots movement. As more patients and caregivers volunteer to review grants and lead support groups, the organization’s influence will continue to scale. The "Take Action" initiative encouraged by Dr. Shanahan is designed to convert the energy of the community into tangible progress, whether through fundraising, legislative advocacy, or scientific review.
As Dr. Shanahan concludes her recent tour, the message is clear: the fight against metastatic breast cancer is being waged on multiple fronts. From the high-level scientific exchanges in San Francisco to the tearful, hopeful gatherings in Philadelphia, the movement is fueled by a unique blend of scientific rigor and profound human connection. For the thousands living with MBC, this advocacy is more than just work—it is a lifeline.
About METAvivor:
METAvivor Research and Support is a non-profit organization dedicated to providing support for women and men living with metastatic breast cancer (MBC) and funding research to improve outcomes for those with Stage IV disease. It is the only national organization that dedicates 100% of its net donations to MBC research.
About the Author
